Acetylsalicylic acid ( Aspirin ) is commonly used for primary and secondary prevention of cardiovascular diseases.
Aspirin use is associated with better outcomes among COVID-19 positive patients.
Researchers have hypothesized that the Aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID-19 susceptibility and disease duration.
A retrospective population-based cross-sectional study, utilizing data from the Leumit Health Services database, was conducted.
The proportion of patients treated with Aspirin was significantly lower among the COVID-19-positive group, as compared to the COVID-19-negative group [ 73 ( 11.03% ) vs 1548 ( 15.77% ); P = 0.001 ].
Aspirin use was associated with lower likelihood of COVID-19 infection, as compared to nonusers ( adjusted odds ratio, OR=0.71 ( 95% CI, 0.52 to 0.99; P = 0.041 ).
Aspirin users were older ( 68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P less than 0.001 ), presented a lower BMI ( 28.77 ± 5.4 vs. 30.37 ± 4.55; P less than 0.0189 ), and showed higher prevalence of hypertension ( 56, 76.71% ), diabetes ( 47, 64.38% ), and COPD ( 11, 15.07% ) than the Aspirin nonusers ( 151, 25.64%, P less than 0.001; 130, 22.07%, P less than 0.001; and 43, 7.3%, P = 0.023, respectively ).
Moreover, COVID-19 disease duration ( considered as the time between the first positive and second negative COVID-19 RT–PCR test results ) among Aspirin users was significantly shorter, as compared to Aspirin nonusers ( 19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045 ).
Among hospitalized COVID-positive patients, a higher proportion of surviving subjects were treated with Aspirin ( 20, 19.05% ), as opposed to 1 dead subject ( 14.29% ), although this difference was not significant ( P = 0.449 ).
In conclusion, researchers have observed an inverse association between the likelihood of COVID-19 infection, disease duration and mortality, and Aspirin use for primary prevention. ( Xagena )
Eugene Merzon E at al, FEBS Journal 2021; 288: 5179–5189